Allogene Therapeutics (ALLO) vs Century Therapeutics (IPSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 137.8% versus a loss of 49.0%. Over five years, IPSC leads with a -93.2% price change compared with -96.5% for ALLO. Allogene Therapeutics is the larger company by market cap ($217.5 million vs $211.6 million), about 1.0 times the size, while Century Therapeutics is growing revenue faster (+1556.8% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | IPSC |
|---|---|---|
| Share price | $0.6277 | $1.17 |
| Market cap | $217.48M | $211.56M |
| 1-day change | -5.88% | -11.74% |
| YTD return | -54.18% | +17.09% |
| 1-year return | -48.97% | +137.76% |
| 5-year return | -96.51% | -93.23% |
| EPS (TTM) | $-0.61 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $109.16M |
| Revenue growth (YoY) | -100.00% | +1556.76% |
| Net income (latest FY) | $-190.89M | $-9.58M |
| Operating margin | — | -15.82% |
| Net margin | — | -8.78% |
| 52-week high | $4.46 | $3.04 |
| 52-week low | $0.6192 | $0.48 |
| Distance from 52-week high | -85.93% | -61.68% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +1333.81% | +307.73% |
| Average volume | 7.69M | 759.69K |
| Shares outstanding | 346.47M | 181.60M |
| Employees | 150 | 78 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed ALLO by 186.7 percentage points over the past year.
- Century Therapeutics grew revenue faster in its latest fiscal year (+1556.76% vs -100.00%).
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
ALLO vs IPSC FAQ
Which is bigger, Allogene Therapeutics or Century Therapeutics?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $217.48M compared with $211.56M for Century Therapeutics (IPSC).
Which stock has performed better over the past year, ALLO or IPSC?
IPSC returned +137.76% over the past 12 months, compared with -48.97% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Century Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.